Shots:
- Bausch Health spin-off its leading eye health business into an independent publicly-traded company under the name Bausch + Lomb. The spinoff is expected to be completed in H1’21
- The spinoff will lead to the formation of two separate companies that include an eye-health company built on the iconic Bausch + Lomb brand and a diversified company with leading positions in gastroenterology, aesthetics/dermatology, neurology, and international pharmaceuticals
- Bausch + Lomb will consist of Bausch Health’s global vision care, surgical, consumer and ophthalmic Rx businesses which had generated $3.7B revenue in 2019. The other company would comprise brands across the Salix, International Rx, neurology and medical dermatology businesses that generated a revenue pf ~$4.9B in 2019
Click here to read full press release/ article | Ref: Bausch Health | Image: Pinterest
